156 related articles for article (PubMed ID: 38750539)
1. Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.
Shi X; Guo S; Duan Q; Zhang W; Gao S; Jing W; Jiang G; Kong X; Li P; Li Y; Teng C; Xu X; Chen S; Nian B; Li Z; Zhong C; Yang X; Zhu G; Du Y; Zhang D; Jin G
J Exp Clin Cancer Res; 2024 May; 43(1):145. PubMed ID: 38750539
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
3. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.
Bao H; Wang Z; Ma X; Guo W; Zhang X; Tang W; Chen X; Wang X; Chen Y; Mo S; Liang N; Ma Q; Wu S; Xu X; Chang S; Wei Y; Zhang X; Bao H; Liu R; Yang S; Jiang Y; Wu X; Li Y; Zhang L; Tan F; Xue Q; Liu F; Cai S; Gao S; Peng J; Zhou J; Shao Y
Mol Cancer; 2022 Jun; 21(1):129. PubMed ID: 35690859
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M; Sudo H; Kawauchi J; Takizawa S; Kondou S; Nobumasa H; Ochiai A
PLoS One; 2015; 10(2):e0118220. PubMed ID: 25706130
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
Zhang X; Wang Z; Tang W; Wang X; Liu R; Bao H; Chen X; Wei Y; Wu S; Bao H; Wu X; Shao Y; Fan J; Zhou J
Hepatology; 2022 Aug; 76(2):317-329. PubMed ID: 34954829
[TBL] [Abstract][Full Text] [Related]
7. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
[TBL] [Abstract][Full Text] [Related]
8. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs.
Kim K; Yoo D; Lee HS; Lee KJ; Park SB; Kim C; Jo JH; Jung DE; Song SY
BMC Med Genomics; 2019 May; 12(1):62. PubMed ID: 31096984
[TBL] [Abstract][Full Text] [Related]
10. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis.
Moldovan N; van der Pol Y; van den Ende T; Boers D; Verkuijlen S; Creemers A; Ramaker J; Vu T; Bootsma S; Lenos KJ; Vermeulen L; Fransen MF; Pegtel M; Bahce I; van Laarhoven H; Mouliere F
Cell Rep Med; 2024 Jan; 5(1):101349. PubMed ID: 38128532
[TBL] [Abstract][Full Text] [Related]
11. Effects of blood-processing protocols on cell-free DNA fragmentomics in plasma: Comparisons of one- and two-step centrifugations.
Hu X; Zhang H; Wang Y; Lin Y; Li Q; Li L; Zeng G; Ou R; Cheng X; Zhang Y; Jin X
Clin Chim Acta; 2024 Jun; 560():119729. PubMed ID: 38754575
[TBL] [Abstract][Full Text] [Related]
12. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma.
Ma X; Chen Y; Tang W; Bao H; Mo S; Liu R; Wu S; Bao H; Li Y; Zhang L; Wu X; Cai S; Shao Y; Liu F; Peng J
J Hematol Oncol; 2021 Oct; 14(1):175. PubMed ID: 34702327
[TBL] [Abstract][Full Text] [Related]
13. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
15. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
16. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
17. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT; Sharifi MN; Sperger JM; Shi Y; Annala M; Bootsma ML; Reese SR; Taylor A; Kaufmann KR; Krause HK; Schehr JL; Sethakorn N; Kosoff D; Kyriakopoulos C; Burkard ME; Rydzewski NR; Yu M; Harari PM; Bassetti M; Blitzer G; Floberg J; Sjöström M; Quigley DA; Dehm SM; Armstrong AJ; Beltran H; McKay RR; Feng FY; O'Regan R; Wisinski KB; Emamekhoo H; Wyatt AW; Lang JM; Zhao SG
Ann Oncol; 2023 Sep; 34(9):813-825. PubMed ID: 37330052
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy.
Hartwig C; Müller J; Klett H; Kouhestani D; Mittelstädt A; Anthuber A; David P; Brunner M; Jacobsen A; Glanz K; Swierzy I; Roßdeutsch L; Klösch B; Grützmann R; Wittenberger T; Sohn K; Weber GF
Mol Cancer; 2024 Feb; 23(1):28. PubMed ID: 38308296
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
